WO2017098533A3 - Process for preparation of lisdexamphetamine - Google Patents

Process for preparation of lisdexamphetamine Download PDF

Info

Publication number
WO2017098533A3
WO2017098533A3 PCT/IN2016/050441 IN2016050441W WO2017098533A3 WO 2017098533 A3 WO2017098533 A3 WO 2017098533A3 IN 2016050441 W IN2016050441 W IN 2016050441W WO 2017098533 A3 WO2017098533 A3 WO 2017098533A3
Authority
WO
WIPO (PCT)
Prior art keywords
lisdexamphetamine
preparation
formula
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
PCT/IN2016/050441
Other languages
French (fr)
Other versions
WO2017098533A2 (en
Inventor
Rajamannar Thennati
Srinivasu Kilaru
Sujit Sridhar PAWAR
Nileshkumar Sureshbhai Patel
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Priority to EP16872573.7A priority Critical patent/EP3386944A4/en
Priority to CA3006537A priority patent/CA3006537A1/en
Priority to BR112018011437A priority patent/BR112018011437A2/en
Publication of WO2017098533A2 publication Critical patent/WO2017098533A2/en
Publication of WO2017098533A3 publication Critical patent/WO2017098533A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/16—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms
    • C07D203/18—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carboxylic acids, or by sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention relates to a process for preparation of lisdexamphetamine and its pharmaceutically acceptable salts via a novel aziridine intermediate of Formula IV.
PCT/IN2016/050441 2015-12-11 2016-12-12 Process for preparation of lisdexamphetamine WO2017098533A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP16872573.7A EP3386944A4 (en) 2015-12-11 2016-12-12 Process for preparation of lisdexamphetamine
CA3006537A CA3006537A1 (en) 2015-12-11 2016-12-12 Process for preparation of lisdexamphetamine
BR112018011437A BR112018011437A2 (en) 2015-12-11 2016-12-12 process for the preparation of lisdexamphetamine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4670MU2015 2015-12-11
IN4670/MUM/2015 2015-12-11

Publications (2)

Publication Number Publication Date
WO2017098533A2 WO2017098533A2 (en) 2017-06-15
WO2017098533A3 true WO2017098533A3 (en) 2017-08-10

Family

ID=59012856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2016/050441 WO2017098533A2 (en) 2015-12-11 2016-12-12 Process for preparation of lisdexamphetamine

Country Status (4)

Country Link
EP (1) EP3386944A4 (en)
BR (1) BR112018011437A2 (en)
CA (1) CA3006537A1 (en)
WO (1) WO2017098533A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022106947A1 (en) 2020-11-18 2022-05-27 Liechti Matthias Emanuel Mdma prodrugs to assist psychotherapy
US11608312B1 (en) 2021-07-22 2023-03-21 Sci Pharmtech Inc. Compound and method for preparation of lisdexamfetamine
EP4122914B1 (en) 2021-07-22 2023-08-16 SCI Pharmtech Inc Compound and method for preparation of lisdexamfetamine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032474A2 (en) * 2003-09-30 2005-04-14 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
WO2010042120A1 (en) * 2008-10-09 2010-04-15 Archimica, Inc. Process for the synthesis of amphetamine derivatives
WO2010148305A1 (en) * 2009-06-19 2010-12-23 Cambrex Charles City, Inc. Methods and compositions for preparation of amphetamine conjugates and salts thereof
WO2013011526A1 (en) * 2011-07-20 2013-01-24 Ind-Swift Laboratories Limited Process for preparation of lisdexamphetamine and salts thereof
US8779191B2 (en) * 2010-12-20 2014-07-15 Cambrex Charles City, Inc. Methods and compositions for preparing lisdexamfetamine and salts thereof
WO2015130660A1 (en) * 2014-02-25 2015-09-03 Chemapotheca, Llc Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032474A2 (en) * 2003-09-30 2005-04-14 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
WO2010042120A1 (en) * 2008-10-09 2010-04-15 Archimica, Inc. Process for the synthesis of amphetamine derivatives
WO2010148305A1 (en) * 2009-06-19 2010-12-23 Cambrex Charles City, Inc. Methods and compositions for preparation of amphetamine conjugates and salts thereof
US8779191B2 (en) * 2010-12-20 2014-07-15 Cambrex Charles City, Inc. Methods and compositions for preparing lisdexamfetamine and salts thereof
WO2013011526A1 (en) * 2011-07-20 2013-01-24 Ind-Swift Laboratories Limited Process for preparation of lisdexamphetamine and salts thereof
WO2015130660A1 (en) * 2014-02-25 2015-09-03 Chemapotheca, Llc Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3386944A4 *

Also Published As

Publication number Publication date
CA3006537A1 (en) 2017-06-15
EP3386944A2 (en) 2018-10-17
EP3386944A4 (en) 2019-08-28
BR112018011437A2 (en) 2018-11-27
WO2017098533A2 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
WO2015110897A3 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
WO2016011390A8 (en) Irak4 inhibiting agents
MX2017003518A (en) Sgc stimulators.
WO2016125191A3 (en) Processes for the preparation of vortioxetine hydrobromide
SG10201808624VA (en) Polymorphs of selinexor
MY197698A (en) Oxysterols and methods of use thereof
WO2015166379A3 (en) Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts
NZ746825A (en) Oxysterols and methods of use thereof
MX2017003517A (en) Sgc stimulators.
WO2015142903A3 (en) Method of controlling lactate production with piperdine-dione derivatives
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
WO2016125192A3 (en) Processes for the preparation of dolute-gravir
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2015121877A3 (en) Polymorphs of lomitapide and its salts
WO2018125880A8 (en) Nrf2 activator
WO2016024284A3 (en) A process for the preparation of mirabegron and its intermediates
WO2015128875A3 (en) A process for preparation of dabigatran etexilate mesylate and intermediates thereof
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
WO2017098533A3 (en) Process for preparation of lisdexamphetamine
WO2015002755A3 (en) Compounds for the treatment of malaria
WO2016088081A8 (en) Processes for the preparation of ertugliflozin
WO2015199418A3 (en) Novel heterocyclic compound
WO2015087343A3 (en) An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16872573

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3006537

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018011437

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2016872573

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016872573

Country of ref document: EP

Effective date: 20180711

ENP Entry into the national phase

Ref document number: 112018011437

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180606